Dexcom Inc banner

Dexcom Inc
NASDAQ:DXCM

Watchlist Manager
Dexcom Inc Logo
Dexcom Inc
NASDAQ:DXCM
Watchlist
Price: 59.32 USD -3.4% Market Closed
Market Cap: $22.8B

Dexcom Inc
Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Dexcom Inc
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Dexcom Inc
NASDAQ:DXCM
Cash Equivalents
$917.7m
CAGR 3-Years
13%
CAGR 5-Years
2%
CAGR 10-Years
27%
Boston Scientific Corp
NYSE:BSX
Cash Equivalents
$2B
CAGR 3-Years
51%
CAGR 5-Years
-1%
CAGR 10-Years
19%
Edwards Lifesciences Corp
NYSE:EW
Cash Equivalents
$2.9B
CAGR 3-Years
50%
CAGR 5-Years
20%
CAGR 10-Years
19%
Stryker Corp
NYSE:SYK
Cash Equivalents
$4B
CAGR 3-Years
30%
CAGR 5-Years
6%
CAGR 10-Years
2%
Abbott Laboratories
NYSE:ABT
Cash Equivalents
$8.5B
CAGR 3-Years
-2%
CAGR 5-Years
1%
CAGR 10-Years
10%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash Equivalents
$2.9B
CAGR 3-Years
38%
CAGR 5-Years
24%
CAGR 10-Years
15%
No Stocks Found

Dexcom Inc
Glance View

Dexcom Inc. emerged as a pioneering force in the realm of continuous glucose monitoring (CGM), redefining the landscape of diabetes management. Founded in 1999, this San Diego-based company disrupted traditional blood glucose monitoring with its innovative technology, allowing individuals to track glucose levels in real-time without frequent finger-pricking. The company’s CGM systems, such as the G6 model, utilize a small sensor inserted beneath the skin that transmits data to a wearable device or smartphone, allowing patients and healthcare providers a comprehensive view of glucose trends. This approach empowers users with critical information for better diabetes management, reducing the likelihood of complications resulting from high or low blood sugar. Dexcom’s revenue generation revolves around the sales of its CGM systems, sensors, and related software services. By selling the initial monitoring devices and disposable sensors that typically need to be replaced every ten days, the company ensures a steady, recurring revenue stream. Furthermore, its integration with healthcare providers and insurers broadens its reach, tapping into a vast network of patients worldwide. Dexcom also collaborates with tech giants to enhance interoperability and data analytics, thereby embedding its solutions in broader digital health ecosystems. As diabetes continues to be a growing global concern, Dexcom’s strategic focus on innovation and strategic partnerships positions it as a leader in the CGM market.

DXCM Intrinsic Value
63.16 USD
Undervaluation 6%
Intrinsic Value
Price $59.32

See Also

What is Dexcom Inc's Cash Equivalents?
Cash Equivalents
917.7m USD

Based on the financial report for Dec 31, 2025, Dexcom Inc's Cash Equivalents amounts to 917.7m USD.

What is Dexcom Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
27%

Over the last year, the Cash Equivalents growth was 51%. The average annual Cash Equivalents growth rates for Dexcom Inc have been 13% over the past three years , 2% over the past five years , and 27% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett